Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Monday 09 March, 2020

JPMorgan Asset Mngt

AbbVie Inc. 8.3

RNS Number : 4607F
JPMorgan Asset Management
09 March 2020
 

Ap19

 

 

FORM   8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.  KEY   INFORMATION

 

Nameofpersondealing (Note 1)

JPMorgan Asset Management

Companydealtin

AbbVie Inc.

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note 2)

US$0.01 common stock

Date of dealing

06 March 2020

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests   and   short   positions   (following   dealing)   in   the   class   of   relevant   security   dealt   in   (Note   3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1)Relevantsecurities

19,592,968*   1.32*

3,126   0.00

(2) Derivatives (other than options)

1,372   0.00

 288,072  0.02

(3)Optionsandagreementstopurchase/sell

 

 

Total

19,594,340*   1.32*

291,198   0.02

             

 

 

*In addition to the dealings in section 2a, there is an increase in the holding of 8 common stock due to a transfer.

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in  (Note   3)

Classofrelevantsecurity:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1)Relevantsecurities

 

 

 

(2) Derivatives (other than options)

 

 

 

(3)Optionsandagreementstopurchase/sell

 

 

Total

 

 

             

 

Ap20

 

 

1.  DEALINGS  (Note   4)

 

(a)  Purchases and sales

 

 

Purchase/sale

 

Numberofrelevantsecurities

 

Priceperunit (Note 5)

Purchase

Purchase

Purchase

 

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

500

632

9,929

 

19

86

5

48

127

1

124

2

5,632

157

87.7189 USD

88.6940 USD

88.8200 USD

 

87.4370 USD

87.4380 USD

87.4400 USD

88.2510 USD

88.2520 USD

88.7900 USD

88.7940 USD

88.7950 USD

88.8200 USD

89.3700 USD

 

 

(b)  Derivatives transactions (other than options transactions)

 

Productname,

e.g. CFD

Natureoftransaction

(Note 6)

Numberofrelevantsecurities

(Note 7)

Priceperunit

(Note 5)

 

 

 

 

 

 

(c)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing, selling, purchasing or varying

 

Productname,

e.g. call option

Writing, selling,purchasing,varyingetc.

Numberofsecurities towhichtheoptionrelates (Note 7)

Exercise price

Type, e.g.American,Europeanetc.

Expiry date

Optionmoney paid/receivedperunit (Note 5)

 

 

 

 

 

 

 

 

 

(ii)  Exercising

 

Productname,

e.g. call option

Numberofsecurities

Exercisepriceper unit (Note 5)

 

 

 

 

 

(d)  Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

Ap21

 

2.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any 

relevant securities to which any derivative referred to on this form is referenced. 

If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached?  (Note   9)    NO

 

Dateofdisclosure

09 March 2020

Contact name

Daniel Swart

Telephone number

0207 134 6168

If aconnectedEFM,nameofofferee/offerorwithwhichconnected

Allergan plc

If aconnectedEFM,statenatureofconnection (Note 10)

Financial Advisor to Allergan plc

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEFLFIFVEIAIII

a d v e r t i s e m e n t